This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Cibinqo (abrocitinib) – a new once daily oral JAK inhibitor​​​​​​​

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1

​​​​​​​Select an option below to learn more about the efficacy, safety and mode of action, and to access dedicated resources to help you support your patients with AD.

Introducing Cibinqo

Discover the benefits that Cibinqo can offer your patients with moderate-to-severe AD.

Learn more about Cibinqo

Cibinqo in action

Learn more about JAK inhibition, the role of the JAK/STAT pathway and how Cibinqo works.

Mode of action overview

Efficacy

Cibinqo has been studied across six Phase III trials as monotherapy or in combination with medicated topical therapies.1–7

Explore the JADE clinical trial programme

Safety

3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

Understand safety guidance

Patient profiles

Discover which patients may be suitable for treatment with Cibinqo.

Learn more

Dosing

Learn more about flexible dosing in patients on Cibinqo.

Oral once daily dosing with Cibinqo

Support and resources

Access resources to help you support your patients on Cibinqo.

Learn more

AD=atopic dermatitis; JAK=Janus kinase; STAT=signal transducer and activator of transcription.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Bieber T, et al. N Eng J Med 2021;384:1101–1112. 3. Simpson E, et al. Lancet 2020;395:P255–266. 4. Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873. 5. Blauvelt A, et al. JAAD 2021;doi.org/10/1016/j.jaad.2021.05.075. 6. Eichenfield L, et al. J Allergy Clin Immunol 2021;AB146:doi.org/10.1016/j.jaci.2020.12.529. 7. ClinicalTrials.gov. NCT03422822. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822.
PP-CIB-GBR-0052. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?